Protagonist Therapeutics’ drug rusfertide reduced the need for phlebotomies as a way to treat the rare blood cancer polycythemia vera. Longer-term Phase 3 data for the Takeda Pharmaceutical-partnered peptide drug were presented during the annual meeting of the American Society of Hematology.
The post Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages appeared first on MedCity News.
StockWatch: Cosmo Surges 40% on Baldness Candidate’s Phase III Data
Cosmo Pharmaceuticals (SIX Swiss: COSM) found itself this past week in the enviable position of attracting welcome attention from investors and other market watchers after
![A leader’s journey through profound grief and loss [PODCAST]](https://i0.wp.com/kevinmd.com/wp-content/uploads/The-Podcast-by-KevinMD-WideScreen-3000-px-4-scaled.jpg?w=0&resize=0,0&ssl=1 "A leader’s journey through profound grief and loss [PODCAST]")